Literature DB >> 18288611

Structural and quantitative comparison of cerebrospinal fluid glycoproteins in Alzheimer's disease patients and healthy individuals.

Carina Sihlbom1, Pia Davidsson, Magnus Sjögren, Lars-Olof Wahlund, Carol L Nilsson.   

Abstract

Glycoproteins in cerebrospinal fluid (CSF) are altered in Alzheimer's Disease (AD) patients compared to control individuals. We have utilized albumin depletion prior to 2D gel electrophoresis to enhance glycoprotein concentration for image analysis as well as structural glycoprotein determination without glycan release using mass spectrometry (MS). The benefits of a direct glycoprotein analysis approach include minimal sample manipulation and retention of structural details. A quantitative comparison of gel-separated glycoprotein isoforms from twelve AD patients and twelve control subjects was performed with glycoprotein-specific and total protein stains. We have also compared glycoforms in pooled CSF obtained from AD patients and control subjects with mass spectrometry. One isoform of alpha1-antitrypsin showed decreased glycosylation in AD patients while another glycosylated isoform of an unassigned protein was up-regulated. Protein expression levels of alpha1-antitrypsin were decreased, while the protein levels of apolipoprotein E and clusterin were increased in AD. No specific glycoform could be specifically assigned to AD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18288611     DOI: 10.1007/s11064-008-9588-x

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  30 in total

1.  Glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of Alzheimer's disease.

Authors:  J Sáez-Valero; L R Fodero; M Sjögren; N Andreasen; S Amici; V Gallai; H Vanderstichele; E Vanmechelen; L Parnetti; K Blennow; D H Small
Journal:  J Neurosci Res       Date:  2003-05-15       Impact factor: 4.164

2.  Identification of glycoproteins in human cerebrospinal fluid with a complementary proteomic approach.

Authors:  Sheng Pan; Yan Wang; Joseph F Quinn; Elaine R Peskind; Dana Waichunas; Jake T Wimberger; Jinghua Jin; Jane G Li; David Zhu; Catherine Pan; Jing Zhang
Journal:  J Proteome Res       Date:  2006-10       Impact factor: 4.466

3.  Sialylation enhances the secretion of neurotoxic amyloid-beta peptides.

Authors:  Kazuhiro Nakagawa; Shinobu Kitazume; Ritsuko Oka; Kei Maruyama; Takaomi C Saido; Yuji Sato; Tamao Endo; Yasuhiro Hashimoto
Journal:  J Neurochem       Date:  2006-01-12       Impact factor: 5.372

Review 4.  Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid.

Authors:  C E Teunissen; J de Vente; H W M Steinbusch; C De Bruijn
Journal:  Neurobiol Aging       Date:  2002 Jul-Aug       Impact factor: 4.673

5.  Reelin expression and glycosylation patterns are altered in Alzheimer's disease.

Authors:  Arancha Botella-López; Ferran Burgaya; Rosalina Gavín; M Salud García-Ayllón; Estrella Gómez-Tortosa; Jordi Peña-Casanova; Jesús M Ureña; José A Del Río; Rafael Blesa; Eduardo Soriano; Javier Sáez-Valero
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-27       Impact factor: 11.205

6.  Comparative proteomic analysis of intra- and interindividual variation in human cerebrospinal fluid.

Authors:  Yan Hu; James P Malone; Anne M Fagan; R Reid Townsend; David M Holtzman
Journal:  Mol Cell Proteomics       Date:  2005-09-30       Impact factor: 5.911

7.  Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease.

Authors:  Maja Puchades; Sara Folkesson Hansson; Carol L Nilsson; Niels Andreasen; Kaj Blennow; Pia Davidsson
Journal:  Brain Res Mol Brain Res       Date:  2003-10-21

8.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.

Authors:  W J Strittmatter; A M Saunders; D Schmechel; M Pericak-Vance; J Enghild; G S Salvesen; A D Roses
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

9.  Towards two-dimensional electrophoresis mapping of the cerebrospinal fluid proteome from a single individual.

Authors:  Erin J Finehout; Zsofia Franck; Kelvin H Lee
Journal:  Electrophoresis       Date:  2004-08       Impact factor: 3.535

10.  Normal levels of clusterin in cerebrospinal fluid in Alzheimer's disease, and no change after acute ischemic stroke.

Authors:  A.-M. Lidström; C. Hesse; L. Rosengren; P. Fredman; P. Davidsson; K. Blennow
Journal:  J Alzheimers Dis       Date:  2001-10       Impact factor: 4.472

View more
  35 in total

1.  The chaperone protein clusterin may serve as a cerebrospinal fluid biomarker for chronic spinal cord disorders in the dog.

Authors:  Intan N F Shafie; Mark McLaughlin; Richard Burchmore; Mary Ann A Lim; Paul Montague; Pamela E J Johnston; Jacques Penderis; Thomas J Anderson
Journal:  Cell Stress Chaperones       Date:  2013-08-29       Impact factor: 3.667

Review 2.  The role of clusterin in Alzheimer's disease: pathways, pathogenesis, and therapy.

Authors:  Jin-Tai Yu; Lan Tan
Journal:  Mol Neurobiol       Date:  2012-01-25       Impact factor: 5.590

3.  Enrichment of glycopeptides for glycan structure and attachment site identification.

Authors:  Jonas Nilsson; Ulla Rüetschi; Adnan Halim; Camilla Hesse; Elisabet Carlsohn; Gunnar Brinkmalm; Göran Larson
Journal:  Nat Methods       Date:  2009-10-18       Impact factor: 28.547

4.  Association of ApoE and LRP mRNA levels with dementia and AD neuropathology.

Authors:  Afia Akram; James Schmeidler; Pavel Katsel; Patrick R Hof; Vahram Haroutunian
Journal:  Neurobiol Aging       Date:  2011-06-15       Impact factor: 4.673

5.  Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impairment.

Authors:  Madhav Thambisetty; Yang An; Anna Kinsey; Deepthi Koka; Muzamil Saleem; Andreas Güntert; Michael Kraut; Luigi Ferrucci; Christos Davatzikos; Simon Lovestone; Susan M Resnick
Journal:  Neuroimage       Date:  2011-07-28       Impact factor: 6.556

6.  Determination of plasma β-amyloids by rolling circle amplification chemiluminescent immunoassay for noninvasive diagnosis of Alzheimer's disease.

Authors:  Danhua Wang; Yibei Dai; Xuchu Wang; Pan Yu; Shufang Qu; Zhenping Liu; Ying Cao; Lingyu Zhang; Ying Ping; Weiwei Liu; Zhihua Tao
Journal:  Mikrochim Acta       Date:  2021-01-06       Impact factor: 5.833

Review 7.  Protein-based biomarkers in cerebrospinal fluid and blood for Alzheimer's disease.

Authors:  Yongyao Fu; Deming Zhao; Lifeng Yang
Journal:  J Mol Neurosci       Date:  2014-06-25       Impact factor: 3.444

8.  HNK-1 Carrier Glycoproteins Are Decreased in the Alzheimer's Disease Brain.

Authors:  María-Salud García-Ayllón; Arancha Botella-López; Inmaculada Cuchillo-Ibañez; Alberto Rábano; Niels Andreasen; Kaj Blennow; Jesús Ávila; Javier Sáez-Valero
Journal:  Mol Neurobiol       Date:  2016-01-06       Impact factor: 5.590

Review 9.  The role of apolipoprotein E in Alzheimer's disease.

Authors:  Jungsu Kim; Jacob M Basak; David M Holtzman
Journal:  Neuron       Date:  2009-08-13       Impact factor: 17.173

10.  Systematic analysis to identify transcriptome-wide dysregulation of Alzheimer's disease in genes and isoforms.

Authors:  Cong Fan; Ken Chen; Jiaxin Zhou; Ping-Pui Wong; Dan He; Yiqi Huang; Xin Wang; Tianze Ling; Yuedong Yang; Huiying Zhao
Journal:  Hum Genet       Date:  2020-11-02       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.